Pfizer Inc. (NYSE:PFE) Stake Lowered by MCF Advisors LLC

MCF Advisors LLC trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 7.7% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 21,301 shares of the biopharmaceutical company’s stock after selling 1,782 shares during the quarter. MCF Advisors LLC’s holdings in Pfizer were worth $591,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. VisionPoint Advisory Group LLC lifted its stake in shares of Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares during the last quarter. GoalVest Advisory LLC lifted its position in shares of Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 811 shares during the last quarter. Creekmur Asset Management LLC bought a new stake in shares of Pfizer during the 4th quarter worth about $32,000. Tennessee Valley Asset Management Partners acquired a new position in shares of Pfizer during the 4th quarter valued at about $36,000. Finally, DiNuzzo Private Wealth Inc. acquired a new stake in Pfizer in the 4th quarter worth approximately $37,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

PFE opened at $27.98 on Friday. The stock’s 50 day simple moving average is $27.90 and its 200-day simple moving average is $27.68. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. The stock has a market cap of $158.55 billion, a PE ratio of -466.26, a P/E/G ratio of 1.10 and a beta of 0.70. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $37.80.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.56 by $0.26. The firm had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business’s revenue for the quarter was down 19.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.23 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be issued a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 6.00%. The ex-dividend date of this dividend is Thursday, July 25th. Pfizer’s payout ratio is -2,799.53%.

Analyst Upgrades and Downgrades

Several equities analysts have commented on PFE shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Wednesday. BMO Capital Markets reiterated an “outperform” rating and issued a $36.00 target price (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Morgan Stanley upped their price target on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. Finally, Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Nine equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $35.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.